The decision about adjuvant therapy is based on the risk of recurrence for any given disease and the likelihood of intervention to reduce the risk of recurrence. Risk of recurrence in patients with stage III colon cancer (all sub-groups included) is 30% or higher and adjuvant therapy is proven effec...

10% to 15% of patients with early-stage, and 4% of patients with metastatic colorectal cancer (CRC) test positive for dMMR. In stage II-III colon cancers, MSI-H/dMMR status is predictive of resistance to 5-fluorouracil as monotherapy, (Sargent et al., PMID 20498393) such that the addition of ox...